Notice of Half Year Results

RNS Number : 3055Z
e-Therapeutics plc
17 September 2015
 

Notification of Half Year Results Date

 

Oxford and Newcastle, UK - 17 September 2015 - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, will announce its half year results for the six months ended 31 July 2015 on Tuesday, 29 September 2015.

 

A group analyst briefing will be held at 11:30am on Tuesday, 29 September 2015 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.

 

Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email e-therapeutics@instinctif.com to register.

 

-Ends-

 

Contacts:

e-Therapeutics plc

Malcolm Young, CEO / Steve Medlicott, Finance Director

Tel: +44 (0)1993 883 125

www.etherapeutics.co.uk

 

Numis Securities Limited

Michael Meade / Freddie Barnfield (Nominated Adviser)

Graeme Summers / James Black (Corporate Broking)

Tel: +44 (0) 20 7260 1000

 

Instinctif Partners

Melanie Toyne Sewell / Jayne Crook

Tel: +44 (0) 20 7457 2020

Email: e-therapeutics@instinctif.com

 

About e-Therapeutics plc

e-Therapeutics is a drug discovery and development company with a proprietary platform in network pharmacology, an innovative approach to drug discovery based on advances in network science and chemical biology. e-Therapeutics' platform is generating more potent, selective and diverse molecules at much higher yields than is reported for conventional drug discovery. The Company's discovery and development activity addresses age-related diseases, including cancer and central nervous system disorders, and it is fully funded to advance its programme into 2019, including phase II clinical data and multiple regulatory submissions.

 

e-Therapeutics has a phase IIb clinical stage drug candidate for major depressive disorder, ETS6103. It has a phase Ib clinical stage candidate in hepatocellular and pancreatic cancer, ETS2101. The company has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400 and Hedgehog pathway inhibition.    

 

e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORQQLFFEKFXBBZ
UK 100

Latest directors dealings